MONTREAL, Jan. 13 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that it has achieved the 3rd milestone in a
series of three Fentanyl TAIFUN(R) Phase 3 study related milestones to be paid
by Janssen Pharmaceutica NV.
